0001209191-22-016242.txt : 20220304 0001209191-22-016242.hdr.sgml : 20220304 20220304162505 ACCESSION NUMBER: 0001209191-22-016242 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220303 FILED AS OF DATE: 20220304 DATE AS OF CHANGE: 20220304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ASADORIAN RAFFI CENTRAL INDEX KEY: 0001628970 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35068 FILM NUMBER: 22714416 MAIL ADDRESS: STREET 1: C/O ACELRX PHARMACEUTICALS, INC. STREET 2: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001427925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 25821 INDUSTRIAL BOULEVARD STREET 2: SUITE 400 CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 650-216-3500 MAIL ADDRESS: STREET 1: 25821 INDUSTRIAL BOULEVARD STREET 2: SUITE 400 CITY: HAYWARD STATE: CA ZIP: 94545 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-03 0 0001427925 ACELRX PHARMACEUTICALS INC ACRX 0001628970 ASADORIAN RAFFI C/O ACELRX PHARMACEUTICALS, INC. 25821 INDUSTRIAL BLVD., SUITE 400 HAYWARD CA 94545 0 1 0 0 Chief Financial Officer Common Stock 2022-03-03 4 F 0 7923 0.4068 D 364205 D Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Balance includes non-reportable acquisition of 4,040 shares of Common Stock through the Company's Employee Stock Purchase Plan. On February 14, 2022, the reporting person filed a Form 4 which inadvertently under-reported his holdings in the Issuer by 8 shares. In addition to reporting the current transactions, this Form 4 serves to correct the reporting person's holdings in the Issuer. /s/ Martha Adler, Attorney-In-Fact 2022-03-04